Did you know?

September 29, 2023. AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma. September 25, 2023. AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma. September 18, 2023.AbbVie celebrates a decade of impact. Over the ten years since launching as an independent company, we’ve solved tough challenges so we can raise the standard of treatment for all, investing over $50 billion to discover and develop new medicines. As we look toward the future, we will continue to innovate and grow, creating medicines and …Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services ...2 AbbVie R&D Pipeline CUG-252* (IL-2 Mutein) SLE CLF065* (GLP-2 agonist) IBD ABBV-151 (GARP+TGFb1) Solid Tumors ABBV-400 (cMet ADC) NSCLC ABBV-647* (PTK7 ADC) NSCLC ABBV-637 (EGFR BCL-xL ADC) NSCLC ABBV-706 (SEZ6 ADC) SCLC ABBV-181 (PD-1) Solid Tumors ABBV-927 (CD40) Solid Tumors JAB-3312* (SHP2) Solid Tumors TTX-030* (CD39) Solid TumorsEligibility for myAbbVie Assist may be initiated through AbbVie Patient Access Support, who will review financial support opportunities for all AbbVie programs, including myAbbVie Assist. If you have insurance, we may review your qualifying financial need based on a combination of your insurance coverage, household income, and out-of-pocket ...We are AbbVie. Powered by 50,000 employees across the globe, it is the responsibility and the privilege of everyone at AbbVie to support our communities, better our society and help the patients of today and tomorrow. Richard A. Gonzalez. Chairman & CEO. Every solution starts with the patient's perspective, because transformative medicines ...AbbVie Product will be used, purchased, leased, ordered, prescribed, recommended, or arranged for or provided formulary or other preferential or qualifying status. I understand that I may not delegate signature authority. I certify that treatment with this medication is medically necessary.AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and ...We would like to show you a description here but the site won’t allow us. My AbbVie Assists provides certain medications at no cost if meet the enrollment guidelines. This is a temporary assistance program that looks at your financial and medical needs. You will not need to pay any co-pays or enrollment fees to get help from this program. Once enrolled, you will receive a supply of the medication in the amount needed ...Find the meaning of your pap smear result and the next steps you should take.©2023 AbbVie H-APP1-23A-1A January 2023 APPLICATION FOR HUMIRA® (adalimumab) myAbbVie Assist provides free medicine to qualifying patients. We review all applications on a case-by-case basis. Participation in our program is free; we do not collect any fees from people seeking our assistance. CHECKLIST FOR SUBMITTING AN APPLICATION ©2023 abbvie page 2 of 4 r-app1-23a-1a january 2023 prescriber prescription and certification to be completed and faxed by prescriber application for drinvoq® (upadacitinib)-617927, ap5 ne; 1 n. waukegan rd north chicago, il 60064 phone: 1-800-222-6885 fax: 1-866-250-2803 1 prescriber information shipping preference NORTH CHICAGO, Ill., Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com.Healthcare Professionals, Get The Answers You Are Searching For Here. Search for information or submit an inquiry to the AbbVie Medical Information team. Begin your search by selecting a product, after which you may select from relevant categories. If you are unable to find documents with the search tool, please fill out the ‘submit inquiry ...We can help identify financial assistance options to support patients in accessing prescribed AbbVie medications, including eligibility for myAbbVie Assist. …View the latest AbbVie Inc. (ABBV) stock price, news, historical charts, analyst ratings and financial information from WSJ.AbbVieAccess.com consolidates AbbVie patient support resources into one location. It's simple to access specific product information such as: online sample requests, patient savings information, and free trial offer detailsmyAbbVie Assist provides free medicine to qualifying patients. If you are uninsured or have limited insurance coverage, you may be eligible to receive ...First time user? Create an account. (844) 729-2236. M-F, 8 AM - 6 PM CT.Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash. Allergic reactions.AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

07/27/23. AbbVie Reports Second-Quarter 2023 Financial Results. Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91 , a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Second ...BOTOX ® (onabotulinumtoxinA) is a prescription medicine that is injected into muscles and used: . To treat overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and urinating often (frequency) in adults 18 years and older when another type of medicine (anticholinergic) does not ...AbbVie's Executive Council on Neglected Diseases coordinates across the company to contribute innovative technologies, diverse compounds for screening and scientific expertise to partners to help address neglected tropical diseases. At AbbVie, more than 400 scientists have given over 170,000 hours of their time toward advancing researchReports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent; These Results Include an Unfavorable Impact of $0.14 Per Share related to Acquired IPR&D and Milestones Expense 1; Delivers Second-Quarter Net Revenues of $14.583 Billion, an Increase of 4.5 Percent on a Reported Basis and 6.1 Percent Operationally

Please print clearly. TO BE COMPLETED BY PATIENT PLEASE SUBMIT THIS PAGE. RINVOQ® (upadacitinib) Patient Access Support: Enrollment Form Fax to AbbVie: 1-866-250-2803 ©2023 AbbVie Page 4 of 5 For full Prescribing Information please visit www.rxabbvie.com R-APP1-23F -1B June 20231-800-252-4415 (USA toll free), 1-847-938-1234 (Outside the US) Or call your regional Global Service Desk. …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. For full Terms and Conditions, visit CREONSaving. Possible cause: AbbVie Assist is offered by AbbVie Inc. and the AbbVie Patient Assistance Fo.